Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Aiforia Technologies

0.94 EUR-5.16 %15.10, 15.17
2,234 following

AIFORIA

First North Finland

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Dividend
Short Selling
Investor views
Compare
-5.16 %
+2.40 %
-46.64 %
-45.40 %
-62.37 %
-65.04 %
-74.61 %
-
-81.48 %

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Read more
Market cap
35.06M EUR
Turnover
38.98K EUR
P/E (adj.) (26e)
-2.6
EV/EBIT (adj.) (26e)
-2.86
P/B (26e)
3.02
EV/S (26e)
14.24
Dividend yield-% (26e)
-
Coverage
Recommendation
Reduce
Target price
1.10 EUR
Updated
31.08.2026
Disclaimer
Antti Luiro
Antti Siltanen
Antti Siltanen, Antti Luiro
Show more
Latest research

Latest analysis report

Released: 31.08.2026

Latest extensive report

Released: 24.04.2025

Revenue and EBIT-%
EPS and dividend
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
3rd party
ShowingAll content types

Forum discussions
Aiforia aloittaa yhteistyön PathAI:n kanssa laajentaakseen tekoälypohjaisen diagnostiikan saatavuutta Aiforia aloittaa yhteistyön PathAI:n kanssa laajentaakseen tekoälypohjaisen diagnostiikan saatavuutta Aiforia Technologies Oyj, Lehdistötiedote, 08.10.2026 klo 09.00 Patologian teko...
10/8/2026, 6:09 AM
by Kulkuri
30
Comments on the latest move LinkedIn #digitalpathology #ai #lifesciences #diagnostics | Paul Atkinson First Roche and PathAI. Now Agilent Technologies and Proscia. 👀 When two of the biggest players in diagnostics make major bets on AI pathology within months of each other, that’s...
yesterday
by Vino Pino
16
Here are Antti’s comments regarding the acquisition of Aiforia’s partner by Agilent, a US-based laboratory and diagnostics company. The cash purchase price is 240 MUSD, with an additional earnout of up to 30 MUSD payable to the sellers. The acquisition continues the industry consolidation...
yesterday
by Sijoittaja-alokas
16
Kotimainen palkinto Aiforialle: Messukeskuksessa juhlittiin suomalaisia maailmanluokan tekoälyratkaisuja – Opetushallitus ja Aiforia nappasivat Vuoden digiteko -palkinnot | Kauppalehti Yritysten sarjan voittaja Aiforia on valjastanut tekoälyn patologien avuksi syöpädiagnostiikkaan...
10/8/2026, 6:27 PM
by NukkeNukuttaja
16
In my opinion, the CEO holds their own quite well in this panel. Sure, this industry is still pretty much in its infancy, but before you know it, we’re all grown up, mourning why we didn’t make the most of those childhood years.
10/1/2026, 11:52 AM
by Salvelinus
12
Näytti Zeroman Oy hypänneen myös Aiforian kelkkaan ja Laakkonen lisänneen reippaasti,kai nämä voi laskea positiivisiksi merkeiksi.
10/1/2026, 4:39 AM
by Salvelinus
12
thepathologist.com The Pathologist | Pathology Visions 2026 – Digital Pathology Conference Aiforia will also be featured there in a few days. Perhaps there will be some bigger news regarding Aiforia soon, as it has been so quiet and insiders haven’t been buying shares either, even...
yesterday
by Salvelinus
11
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Aiforia's partner Proscia acquired by Agilent
Analyst Comment14.10.2026, 08.39 by
Antti Siltanen

Aiforia's partner Proscia acquired by Agilent

Two of Aiforia's key platform partners are now owned by large corporations.

Aiforia Technologies
Aiforia enters into an agreement with PathAI
Analyst Comment09.10.2026, 07.05 by
Antti Siltanen

Aiforia enters into an agreement with PathAI

The partnership expands the distribution network in the US and thus supports our growth estimates.

Aiforia Technologies
Press release08.10.2026, 08.00

Aiforia collaborates with PathAI to broaden access to AI-driven diagnostics

Aiforia Technologies

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release24.09.2026, 09.15

Aiforia Technologies Plc: Share subscriptions based on stock options 2016B

Aiforia Technologies
Analyst Comment09.09.2026, 06.35

Børsurougen | Sundhed & Vækst og M&A 8.9.2026

Børsinvestorens ugentlige temaer Sundhed samt Vækst & M&A kan ses på inderesTV.

Aiforia TechnologiesTerveystaloOrionRelais GroupAspo
Modelportfolio: Vi har ryddet ud i den mislykkede Aiforia-investering i porteføljen
Research02.09.2026, 09.00 by
Juha Kinnunen, Atte Riikola, Rauli Juva

Modelportfolio: Vi har ryddet ud i den mislykkede Aiforia-investering i porteføljen

I vores vækstinvestering med høj risiko udeblev væksten, hvilket ødelagde vores oprindelige investeringsteser.

Aiforia Technologies
Third party research02.09.2026, 08.08

Aiforia Technologies: H1'26 review: costs above expectations; est. & PT chg. - NuWays AG Research

Aiforia published its H1'26 report last Friday. Revenue of € 0.75m (-46% yoy) was already knownfrom the July profit warning, which we attributed to the absence of onboarding revenue and a slower than expected usage ramp up of existing clinical clients...

Aiforia Technologies
Aiforia H1'26: Still a long way to go before reaching profitability
Research31.08.2026, 13.26 by
Antti Siltanen, Antti Luiro

Aiforia H1'26: Still a long way to go before reaching profitability

Earnings fell short of our expectations due to both a one-off expense and a more permanent increase in the cost structure.

Aiforia Technologies
Aiforia, Webcast, Q2'26
Webcast28.08.2026, 09.00

Aiforia, Webcast, Q2'26

Aiforia Technologies
Regulatory press release28.08.2026, 08.00

Aiforia’s Half-Year Financial Report January-June 2026: Financing arrangements and new customers support future growth, revenue remained below the comparison period's level

Aiforia Technologies
Aiforia lands new partnership in breast cancer diagnostics
Analyst Comment26.08.2026, 09.59 by
Antti Siltanen

Aiforia lands new partnership in breast cancer diagnostics

The new partnership brings predictive risk profiling into diagnostics and can reduce the need for expensive genetic tests.

Aiforia Technologies
Aiforia H1'26 preview: Profit warning increased concerns about commercial progress
Analyst Comment26.08.2026, 12.00 by
Antti Siltanen

Aiforia H1'26 preview: Profit warning increased concerns about commercial progress

Contract delays caused H1 revenue to collapse to 0.75 MEUR and increased concerns about commercial performance.

Aiforia Technologies
Press release25.08.2026, 08.30

Aiforia and Stratipath partner to expand access to AI-driven precision diagnostics in oncology

Aiforia Technologies
Press release19.08.2026, 07.00

Aiforia to publish January–June 2026 Half-Year Financial Report on August 28, 2026

Aiforia Technologies
Aiforia secured a 20 MEUR financing agreement with the EIB
Analyst Comment03.08.2026, 08.19 by
Antti Siltanen, Antti Luiro

Aiforia secured a 20 MEUR financing agreement with the EIB

The loan arrangement secures financing for the coming years, provided the business develops favorably.

Aiforia Technologies
Regulatory press release31.07.2026, 17.00

Aiforia and the European Investment Bank have signed an agreement for EUR 20 million venture debt financing

Aiforia Technologies
Regulatory press release24.07.2026, 10.00

Aiforia Technologies Plc – Managers’ Transactions – Jukka Tapaninen

Aiforia Technologies
Third party research23.07.2026, 09.04

Aiforia Technologies: Aiforia H1 profit warning triggers downgrade to HOLD - NuWays AG Research

Aiforia issued a profit warning with H1'26 revenues coming in at a mere € 0.75m, down from € 1.4m in H1'25 (-46% yoy), against our expectation of roughly doubling yoy, following last year's strong Clinical momentum (organic growth of +65%). At the same...

Aiforia Technologies
Aiforia: We diagnose a growth deficiency
Research23.07.2026, 09.25 by
Antti Siltanen

Aiforia: We diagnose a growth deficiency

The ongoing uncertainty regarding growth is causing us to take a negative view of the risk-reward ratio.

Aiforia Technologies
Aiforia's H1 revenue was surprisingly subdued
Analyst Comment22.07.2026, 08.05 by
Antti Siltanen

Aiforia's H1 revenue was surprisingly subdued

The conversion of customer wins into revenue continues to be slow.

Aiforia Technologies